Open Access, Peer-reviewed
pISSN 2005-0380   eISSN 2005-0399
    Korean J Gynecol Oncol. 2008 Mar;19(1):75-80. Korean.
    Published online Mar 20, 2008.
    https://doi.org/10.3802/kjgo.2008.19.1.75
    Copyright © 2008 Korean Society of Gynecologic Oncology and Colposcopy
    Original Article

    Clinical analysis for the prognostic factors in patients with recurrent epithelial ovarian cancer who underwent secondary cytoreductive surgery

    Hee Seung Kim, Tae Hun Kim, Hyun Hoon Chung, Jae Weon Kim, Noh-Hyun Park, Yong-Sang Song and Soon-Beom Kang
      • Department of Obstetrics and Gynecology, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
    • Address reprint requests to Jae Weon Kim. Department of Obstetrics and Gynecology, Cancer Research Institute, Seoul National University College of Medicine 28, Yeongeon-dong, Jongno-gu, Seoul 110-744, Korea. Tel: 82-2-2072-3511, Fax: 82-2-762-3599, Email: kjwksh@snu.ac.kr
    Received February 12, 2008; Accepted March 03, 2008.

    Abstract

    Objective

    To identify clinical prognostic factor improving survival of recurrent epithelial ovarian cancer (EOC) patients treated with secondary cytoreductive surgery (SCS).

    Methods

    The indications of SCS were as follows; 1) complete response (CR) after primary cytoreductive surgery and adjuvant chemotherapy, 2) disease-free survival (DFS) (≥6 months). Clinical data of 17 patients including age, DFS, peritoneal seeding identified during SCS, the number of recurrent tumors (≥1 cm), serum CA-125 levels and maximal diameter of residual tumor after SCS were reviewed retrospectively between January 1990 and March 2007. Survival analyses were performed using Kaplan-Meier method with log-rank test and univariate Cox's regression analysis.

    Results

    Mean age of them was 51.7 years. No peritoneal seeding identified during SCS was a prognostic factor improving progression-free survival after SCS (PFS-SCS) (30 vs. 6 months, p<.01 hazard ratio 0.099, 95% confidence interval 0.011-0.929, p=.043). Furthermore, serum CA-125 level (≤37 U/ml) after SCS was a significant prognostic factors improving overall survival (51 vs. 19 months, p=.033; hazard ratio 0.212, 95% confidence interval 0.045-0.983, p=.045).

    Conclusion

    Serum CA-125 levels with normal value after SCS and no peritoneal seeding may be associated with the improvement of survival in recurrent epithelial ovarian cancer patients treated with SCS.

    Keywords
    Secondary cytoreductive surgery; Prognostic factor; Recurrent; Epithelial ovarian cancer

    Figures

    Fig. 1
    Kaplan-Meier survival analysis with log-rank test for progression-free survival after secondary cytoreductive surgery (PFS-SCS) according to peritoneal seeding identified during secondary cytoreductive surgery (30 vs. 6 months, p=.0089).

    Fig. 2
    Kaplan-Meier survival analysis with log-rank test for overall survival (OS) according to serum CA-125 levels after secondary cytoreductive surgery (51 vs. 19 months, p=.033).

    Tables

    Table 1
    General characteristics of 17 patients with recurrent epithelial ovarian cancer who underwent secondary cytoreductive surgery

    References

      1. 2002 Annual Report of the Korea Central Cancer Registry. [Last accessed: November 18, 2007].
        Available at: http://www.ncc.re.kr/index.jsp.
      1. Chung HH, Hwang SY, Jung KW, Won YJ, Shin HR, Kim JW, et al. Ovarian cancer incidence and survival in Korea: 1993-2002. Int J Gynecol Cancer 2007;17:595–600.
      1. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 2004;95:273–280.
      1. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320–1329.
      1. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–3200.
      1. Polverino G, Parazzini F, Stellato G, Scarfone G, Cipriani S, Bolis G. Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. Gynecol Oncol 2005;99:343–347.
      1. Scarabelli C, Gallo A, Garbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001;83:504–512.
      1. Tay E, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002;99:1008–1013.
      1. Uzan C, Morice P, Rey A, Pautier P, Camatte S, Lhomme C, et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann Surg Oncol 2004;11:658–664.
      1. Tebes SJ, Sayer RA, Palmer JM, Tebes CC, Martino MA, Hoffman MS. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2007;106:482–487.
      1. Santillan A, Karam AK, Li AJ, Giuntoli R 2nd, Gardner GJ, Cass I, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 2007;104:686–690.
      1. Benedetii Panici P, De vivo A, Bellati F, Manci N, Perniola G, Basile S, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 2007;14:1136–1142.
      1. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106:1933–1939.
      1. Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Garder GJ, Amstrong DK, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: Analysis of prognostic factors and survival outcome. Cancer 2007;109:685–691.
      1. Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y. Seconadry cytoreductive surgery for recurrent epithelial ovarian carcinoma proposal for patients selection. Br J Cancer 2005;92:1026–1032.
      1. Meier W, Stieber P, Hasholzner U, Gropp M, Fateh-Moghadam A. Prognostic significance of CA 125 in patients with ovarian cancer and secondary debulking surgery. Anticancer Res 1997;17:2945–2947.
      1. Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 2004;100:1152–1161.
      1. Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P, et al. Cytoreductive surgery and intraperitoenal chemohyperthermia for recurrent peritoneal carcionomatosis from ovarian cancer. World J Surg 2004;28:1040–1045.
      1. Gadducci A, Cosio S, Zola P, Landoni F, Maggino T, Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: A review of the literature. Int J Gynecol Cancer 2007;17:21–31.
      1. Leitao MM Jr, Kardos S, Barakat RR, Chi DS. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol 2004;95:181–188.
    Cited by
    Crossref 5
    Google Scholar 
    MeSH Terms
    Chemotherapy, Adjuvant
    Disease-Free Survival
    Humans
    Neoplasm, Residual
    Neoplasms, Glandular and Epithelial
    Ovarian Neoplasms
    Reference Values
    Retrospective Studies
    Seeds
    Metrics
    Figures
    slide
    slide

    1 / 2

    Tables
    slide

    1 / 1

    ORCID IDs
    PERMALINK